Search
forLearn
5 / 801 resultslearn ACETYL TETRAPEPTIDE-2
learn glutamic acid
learn KY19382
compound that activates Wnt/β-catenin to promote hair regrowth and create new hair follicles
learn Actsyl®
Research
5 / 460 results
research Topical sodium valproate-loaded nanospanlastics versus conventional topical steroid therapy in alopecia areata: a randomized controlled study
Both treatments for alopecia areata showed similar modest effectiveness.
research Impact of substrate stiffness on dermal papilla aggregates in microgels
Softer hydrogel surfaces help maintain hair growth-related functions in skin cells.
research 산사 열수추출물의 모발 성장과 모유두세포의 성장인자 유전자 발현에 대한 영향
Crataegi Fructus water extract helps hair grow better and thicker.
research Augmenting Endogenous Wnt Signaling Improves Skin Wound Healing
Boosting Wnt signaling improves skin wound healing.
research Tectoridin Stimulates the Activity of Human Dermal Papilla Cells and Promotes Hair Shaft Elongation in Mouse Vibrissae Hair Follicle Culture
Tectoridin helps human hair cells grow and makes mouse hair longer, suggesting it could treat hair loss.
Community Join
5 / 1000+ resultscommunity Novel Formulation To Put An End To Hair Loss Once And For All.
A pharmacy student proposed a hair loss treatment using minoxidil, finasteride, clascoterone, and tretinoin, aiming for high effectiveness with minimal side effects. Reactions were mixed, with some questioning its feasibility and others showing interest.
community Selling KY19382 powder a novel activator of Wnt/β-catenin signaling Product
Selling KY19382 powder, a novel activator of Wnt/β-catenin signaling, and Kolliphor EL liquid for vehicle formulation. KY19382 is a growth agonist.
community Kintor Has Completed Enrollment in Phase II Clinical Trial of KX-826 (Pyrilutamide) for Treatment of Male AGA Patients in the US
KX-826 (Pyrilutamide) being tested in the US for hair loss treatment and that they have found enough people to participate in phase II clinical trials. Other treatments discussed are Minoxidil, finasteride, and RU58841.
community Kintor Pharma Announced Successful Dosing of the First Patient for Acne Vulgaris Phase II Clinical Trial of KX-826
Kintor Pharma successfully dosed the first patient in a Phase II trial for KX-826 for acne vulgaris. Users are more interested in results for male pattern baldness (MPB).
community KX-826 Phase II Results Just Dropped (Male AGA) – Key Takeaways
KX-826 Phase II results show that a 0.5% concentration performs better than 1% for treating male pattern baldness. Concerns about receptor upregulation from long-term DHT antagonism were mentioned.